The Place and Importance of SBRT in Early Stage NSCLC

Kaynakça (1)

1. Ginsberg RJ, Rubinstein LV, Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60(3):615-22; discussion 622. [CrossRef] 2. Singhal S, Shrager JB, Kaiser LR. Multimodality therapy for non-small-cell lung cancer. In: Shields TW, LoCicero III J, eds., Ponn Rb, Rusch VW, eds. General Thoracic Surgery. 6th ed Philedelphia, USA: Lippincott Williams and Wilkins; 2005: 1653-79. 3. Tamura M, Matsumoto I, Tanaka Y, et al. Comparison Between stereotactic radiotherapy and sublobar resection for non-small cell lung cancer. Ann Thorac Surg. 2019 May;107(5):1544- 1550. [CrossRef] 4. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival following lobectomy vs. limited resection for stage I lung cancer: A meta-analysis. Br J Cancer. 2005;92(6):1033- 1037. [CrossRef] 5. Rineer J, Schreiber D, Katsoulakis E, et al. Survival following sublobar resection for early-stage non-small cell lung cancer with or without adjuvant external beam radiation therapy: A population-based study. Chest. 2010;137(2):362-368. [CrossRef] 6. Rosen JE, Salazar MC, Wang Z, et al. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2016;152(1):44-54.e9. [CrossRef] 7. Birdas TJ, Koehler RPM, Colonias A, et al. Sublobar resection with brachytherapy versus lobectomy for stage 1B non-small cell lung cancer. Ann Thorac Surg. 2006;81(2):434-8; discussion 438. [CrossRef] 8. Yerokun BA, Yang CJ, Gulack BC, et al. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2017 August;154(2):675-686.e4. [CrossRef] 9. Ackerson BG, Tong BC, Hong JC, et al. Stereotactic body radiation therapy versus sublobar resection for stage I NSCLC. Lung Cancer. 2018 November;125:185-191. [CrossRef] 10. Palma DA, Nguyen TK, Kwan K, et al. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). Radiat Oncol. 2017 January 27;12(1):30. [CrossRef] 11. Hou Y, Hermann G, Lewis JH, et al. Clinical outcomes After lung stereotactic body radiation therapy in patients With or Without a prior lung resection. Am J Clin Oncol. 2018 July;41(7):695-701. [CrossRef]